NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to treat major neuropsychiatric ...

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...

Bavarian Nordic has sold a PRV for $160m, a day after the FDA announced a new scheme utilising the fast-track tickets.

Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for zagociguat.

FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.